Polycystic ovary syndrome(PCOS)is clinically characterized by insulin resistance,ovulatory dysfunction and hyperandrogenemia,often accompanied by obesity,type 2 diabetes,and dyslipidemia.This article reviews the recent studies on the intervention of PCOS with herbal medicines,including traditional Chinese medicine(TCM)compound formulas and single active compounds.The results demonstrate that both TCM compound formulas and single active compounds are effective on improving PCOS symptoms,with the advantages of multi-target actions and personalized treatment.TCM compound formulas for PCOS can be categorized into kidney-tonifying formulas(e.g.,Antai Fanglou Decoction,Gui Zhu Yikun Formula,Liuwei Dihuang Pills,Bushen Huayu Formula),phlegm-resolving formulas(e.g.,Cang Fu Daotan Decoction,Erchen Decoction),liver-soothing formulas(e.g.,Xiaoyao San,Shaoyao Gancao Decoction),and blood-activating formulas(e.g.,Jiawei Shaoyao Gancao Decoction,Gexia Zhuyu Decoction,Huayu Xiaozheng Decoction).These compound formulas separately exhibit actions of tonifying kidney essence,soothing liver and relieving depression,and activating blood circulation to resolve stasis,which are aligned with the TCM etiology and pathogenesis of PCOS.Single active compounds from herbal medicine primarily include flavonoids,alkaloids,terpenoids and polyphenols.Extractives from herbal medicines exert therapeutic effects by inhibiting ovarian inflammatory responses and relieveing hyperandrogenemia insulin resistance.Key signaling pathways for the intervention of PCOS with TCM include PI3K/AKT/mTOR,SIRT1/AMPK,TLR4/NF-κB,IRS1/PI3K/GLUT4,RIP1/RIP3/MLKL,HMGB1/RAGE,and Hippo-YAP.The review of recent advances in TCM formulas and single active compounds for the treatment of PCOS along with their underlying mechanisms will provide valuable insights for clinical management and new drug development for PCOS.

Polypoidal choroidal vasculopathy (PCV) is a disease characterized by polypoidal lesions and/or branching vascular networks (BVN), with recurrent serous or hemorrhagic retinal pigment epithelial detachment as manifestations, and causes loss of central vision.Although PCV is considered to be a subtype of neovascular age-related macular degeneration (nAMD), its response to anti-vascular endothelial growth factor treatment is somewhat different from that of nAMD, which makes it essential to make a definitive diagnosis of PCV.The gold standard for PCV diagnosis is indocyanine green angiography (ICGA), but ICGA has disadvantages such as allergies, invasive examinations, and not being widely popularized.Compared with ICGA, optical coherence tomography angiography (OCTA) can detect the BVN of PCV patients more precisely, and its combination with optical coherence tomography, color fundus photography and other multimodal imaging technologies can significantly improve the detection rate of polypoidal lesions.In addition, OCTA can present the location, morphology, three-dimensional anatomical structure and origin of polyps and BVN.Besides, OCTA is able to assess prognosis in PCV patients, and because OCTA is a non-invasive examination, it can be repeatedly used in the treatment monitoring of PCV patients.This article sums and discusses the role of OCTA in the diagnosis and treatment of PCV.

Polypoidal choroidal vasculopathy (PCV) is a disease characterized by polypoidal lesions and/or branching vascular networks (BVN), with recurrent serous or hemorrhagic retinal pigment epithelial detachment as manifestations, and causes loss of central vision.Although PCV is considered to be a subtype of neovascular age-related macular degeneration (nAMD), its response to anti-vascular endothelial growth factor treatment is somewhat different from that of nAMD, which makes it essential to make a definitive diagnosis of PCV.The gold standard for PCV diagnosis is indocyanine green angiography (ICGA), but ICGA has disadvantages such as allergies, invasive examinations, and not being widely popularized.Compared with ICGA, optical coherence tomography angiography (OCTA) can detect the BVN of PCV patients more precisely, and its combination with optical coherence tomography, color fundus photography and other multimodal imaging technologies can significantly improve the detection rate of polypoidal lesions.In addition, OCTA can present the location, morphology, three-dimensional anatomical structure and origin of polyps and BVN.Besides, OCTA is able to assess prognosis in PCV patients, and because OCTA is a non-invasive examination, it can be repeatedly used in the treatment monitoring of PCV patients.This article sums and discusses the role of OCTA in the diagnosis and treatment of PCV.

Objective To study the protective effect of Wedelolactone(WEL)against inflammatory injury in human umbilical vein endothelial cells(HUVECs)and its molecular mechanism by inducing PI3K/Akt/mTOR.Methods The model of atherosclerosis(AS)oxidative stress injury in HUVECs was induced with 200 μmol·L-1 of hydrogen peroxide for 24 h.The experimental groups were as follows:normal control group,DMSO(dimethyl sulfoxide)group,H2O2 group,and WEL group.MTT was used to measure the cell survival rate of each group;flow cytometry was used to assess intracellular ROS levels;fluorescence microscopy was used to detect the expression of p62 protein;immunoblotting assay was used to determine the protein expression levels for apoptosis-related proteins associated with PI3K/Akt/mTOR signaling pathway and autophagy-related proteins.Results Compared with the H2 O2 group,the HUVEC cell survival rate was significantly inhibited in the WEL group(P＜0.05).ROS production was significantly lower,and the protein expressions of SOD1 and p62 were significantly increased in the WEL group as compared to the hydrogen peroxide group.The protein expression of p-mTOR,p-Akt,and p-PI3K was significantly decreased in hydrogen peroxide(P＜0.01);In the WEL experiment,p-mTOR,p-Akt,and p-PI3K were increased significantly in the post-injury HUVECs(P＜0.01).Conclusion Wedelolactone inhibits HUVECs'autophagy by suppressing H2O2-induced inflammatory damage in HUVECs,which may be related to the fact that WEL promotes the phosphorylation of PI3K,Akt,and mTOR proteins,inhibits autophagy and thus resists oxidative stress damage in HUVECs cells.

Robotic natural orifice specimen extraction surgery for right colon cancer has been conducted with progressive refinements. To facilitate the standardized implementation of this surgical technique, the adoption of rigorous quality control measures is paramount. The present article outlines the key aspects of quality control for robotic natural orifice specimen extraction right hemicolectomy surgery, encompassing the preoperative, intraoperative, and postoperative phases, as well as the training and credentialing requirements for the operating surgeons, with the aim of providing a reference framework to facilitate the safe and reliable implementation and dissemination of this minimally invasive approach for right colon cancer.

Objective:To compare the surgical outcomes of robotic natural orifice specimen extraction surgery (NOSES) and robotic-assisted radical resection for rectal cancer.Methods:A retrospective analysis using propensity score matching (PSM) was conducted on 547 patients who had undergone radical resection of rectal cancer at the First Affiliated Hospital of Nanchang University from June 2018 to March 2024. The study cohort comprised 157 patients in the robotic NOSES group and 390 in the robotic-assisted group. PSM was used in a 1:1 manner to match relevant general clinical preoperative data of the study patients (age, sex, body mass index, preoperative comorbidities, abnormal preoperative carcinoembryonic antigen (>6.5 μg/L) and carbohydrate antigen 19-9 levels (>27 kU/L), preoperative American Society of Anesthesiologists score, tumor diameter, tumor distance from the anal margin, and TNM stage), with a clamp value of 0.05. After performing PSM to match the general clinical data of the two groups of patients, 77 patients in each of the robotic NOSES and robotic-assisted groups were included in the analysis. We found no statistically significant difference in preoperative general clinical data between the robot NOSES and robot-assisted groups ( P>0.05). We compared the surgical outcomes, postoperative recovery, postoperative pathological data, and incidence of complications between the robotic NOSES and robot-assisted groups. Results:Compared with the robot-assisted groups. the robot NOSES group had a significantly shorter time to first postoperative passage of flatus (48 [38, 50] hours vs. 56 [50, 60] hours, Z=-7.513, P<0.001), time to taking a liquid diet (60 [54,63] hours vs. 66 [62, 72] hours, Z=-6.303, P<0.001), lower pain scores (3 [3, 4] vs. 4 [4, 5], Z=-5.237, P<0.001), and lower incision infection rates (0 vs. 5 [6.5%], χ 2=5.237, P=0.028) within 24 hours after surgery ( P<0.05). However, there were no significant differences in surgical time, intraoperative blood loss, postoperative hospital stay, postoperative anastomotic complications, or incidence of other complications between the two groups (all P>0.05). Conclusion:Robotic NOSES surgery is a safe and feasible procedure for resecting rectal cancer and postoperative recovery is faster after robotic NOSES than after standard robot-assisted surgery.

Robotic natural orifice specimen extraction surgery for right colon cancer has been conducted with progressive refinements. To facilitate the standardized implementation of this surgical technique, the adoption of rigorous quality control measures is paramount. The present article outlines the key aspects of quality control for robotic natural orifice specimen extraction right hemicolectomy surgery, encompassing the preoperative, intraoperative, and postoperative phases, as well as the training and credentialing requirements for the operating surgeons, with the aim of providing a reference framework to facilitate the safe and reliable implementation and dissemination of this minimally invasive approach for right colon cancer.

Objective:To compare the surgical outcomes of robotic natural orifice specimen extraction surgery (NOSES) and robotic-assisted radical resection for rectal cancer.Methods:A retrospective analysis using propensity score matching (PSM) was conducted on 547 patients who had undergone radical resection of rectal cancer at the First Affiliated Hospital of Nanchang University from June 2018 to March 2024. The study cohort comprised 157 patients in the robotic NOSES group and 390 in the robotic-assisted group. PSM was used in a 1:1 manner to match relevant general clinical preoperative data of the study patients (age, sex, body mass index, preoperative comorbidities, abnormal preoperative carcinoembryonic antigen (>6.5 μg/L) and carbohydrate antigen 19-9 levels (>27 kU/L), preoperative American Society of Anesthesiologists score, tumor diameter, tumor distance from the anal margin, and TNM stage), with a clamp value of 0.05. After performing PSM to match the general clinical data of the two groups of patients, 77 patients in each of the robotic NOSES and robotic-assisted groups were included in the analysis. We found no statistically significant difference in preoperative general clinical data between the robot NOSES and robot-assisted groups ( P>0.05). We compared the surgical outcomes, postoperative recovery, postoperative pathological data, and incidence of complications between the robotic NOSES and robot-assisted groups. Results:Compared with the robot-assisted groups. the robot NOSES group had a significantly shorter time to first postoperative passage of flatus (48 [38, 50] hours vs. 56 [50, 60] hours, Z=-7.513, P<0.001), time to taking a liquid diet (60 [54,63] hours vs. 66 [62, 72] hours, Z=-6.303, P<0.001), lower pain scores (3 [3, 4] vs. 4 [4, 5], Z=-5.237, P<0.001), and lower incision infection rates (0 vs. 5 [6.5%], χ 2=5.237, P=0.028) within 24 hours after surgery ( P<0.05). However, there were no significant differences in surgical time, intraoperative blood loss, postoperative hospital stay, postoperative anastomotic complications, or incidence of other complications between the two groups (all P>0.05). Conclusion:Robotic NOSES surgery is a safe and feasible procedure for resecting rectal cancer and postoperative recovery is faster after robotic NOSES than after standard robot-assisted surgery.

Objective:To investigate the clinical features and therapeutic efficacy of patients with hereditary leiomyomatosis and renal cell carcinoma(RCC) syndrome-associated RCC (HLRCC-RCC) in China.Methods:The clinical data of 119 HLRCC-RCC patients with fumarate hydratase (FH) germline mutation confirmed by genetic diagnosis from 15 medical centers nationwide from January 2008 to December 2021 were retrospectively analyzed. Among them, 73 were male and 46 were female. The median age was 38(13, 74) years. The median tumor diameter was 6.5 (1.0, 20.5) cm. There were 38 cases (31.9%) in stage Ⅰ-Ⅱand 81 cases (68.1%) in stage Ⅲ-Ⅳ. In this group, only 11 of 119 HLRCC-RCC patients presented with skin smooth muscle tumors, and 44 of 46 female HLRCC-RCC patients had a history of uterine fibroids. The pathological characteristics, treatment methods, prognosis and survival of the patients were summarized.Results:A total of 86 patients underwent surgical treatment, including 70 cases of radical nephrectomy, 5 cases of partial nephrectomy, and 11 cases of reductive nephrectomy. The other 33 patients with newly diagnosed metastasis underwent renal puncture biopsy. The results of genetic testing showed that 94 patients had FH gene point mutation, 18 had FH gene insertion/deletion mutation, 4 had FH gene splicing mutation, 2 had FH gene large fragment deletion and 1 had FH gene copy number mutation. Immunohistochemical staining showed strong 2-succinocysteine (2-SC) positive and FH negative in 113 patients. A total of 102 patients received systematic treatment, including 44 newly diagnosed patients with metastasis and 58 patients with postoperative metastasis. Among them, 33 patients were treated with tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor (ICI), 8 patients were treated with bevacizumab combined with erlotinib, and 61 patients were treated with TKI monotherapy. Survival analysis showed that the median progression-free survival (PFS) of TKI combined with ICI was 18 (5, 38) months, and the median overall survival (OS) was not reached. The median PFS and OS were 12 (5, 14) months and 30 (10, 32) months in the bevacizumab combined with erlotinib treatment group, respectively. The median PFS and OS were 10 (3, 64) months and 44 (10, 74) months in the TKI monotherapy group, respectively. PFS ( P=0.009) and OS ( P=0.006) in TKI combined with ICI group were better than those in bevacizumab combined with erlotinib group. The median PFS ( P=0.003) and median OS ( P=0.028) in TKI combined with ICI group were better than those in TKI monotherapy group. Conclusions:HLRCC-RCC is rare but has a high degree of malignancy, poor prognosis and familial genetic characteristics. Immunohistochemical staining with strong positive 2-SC and negative FH can provide an important basis for clinical diagnosis. Genetic detection of FH gene germ line mutation can confirm the diagnosis. The preliminary study results confirmed that TKI combined with ICI had a good clinical effect, but it needs to be confirmed by the results of a large sample multi-center randomized controlled clinical study.

The Vaccine Adverse Event Reporting System (VAERS) in the United States is the earliest vaccine safety surveillance system in the world, established in 1990. The VAERS database can be used to detect new, unusual, or rare adverse events following vaccine to identify potential safety issues with marketed vaccines. This paper introduces the basic situation and data acquisition methods of VAERS database, summarizes the format, content, relevance and practical application methods of VAERS data packet, and reviews the research on vaccine safety data analysis and signal mining by foreign scholars using VAERS data in recent years, so as to provide reference for Chinese scholars in use of VAERS database and the data opening of surveillance data of suspected adverse event following immunization in China.